Showing results (641-650 of 3,353) with videos related to

Sort By:
Pageof 336
The Lancet. Oncology|December 8, 2016
Relevance of randomised controlled trials in oncologyIan F Tannock, Eitan Amir, Christopher M Booth, et al.
The Lancet. Oncology|March 28, 2017
Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trialToshiaki Takahashi, Takeharu Yamanaka, Takashi Seto, et al.
The Lancet. Oncology|March 8, 2019
Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemiaDavid T Teachey, Ching-Hon Pui
The Lancet. Oncology|February 16, 2019
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trialSherene Loi, Anita Giobbie-Hurder, Andrea Gombos, et al.
The Lancet. Oncology|February 17, 2019
Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trialBertrand Tombal, Fred Saad, David Penson, et al.
The Lancet. Oncology|March 15, 2017
Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trialEvan W Alley, Juanita Lopez, Armando Santoro, et al.
The Lancet. Oncology|March 12, 2017
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trialKim N Chi, Celestia S Higano, Brent Blumenstein, et al.
The Lancet. Oncology|February 19, 2017
Recommendations for gonadotoxicity surveillance in male childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup ConsortiumRoderick Skinner, Renee L Mulder, Leontien C Kremer, et al.
The Lancet. Oncology|March 13, 2019
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket studyFunda Meric-Bernstam, Herbert Hurwitz, Kanwal Pratap Singh Raghav, et al.
The Lancet. Oncology|August 10, 2019
Cancer control in small island nations: from local challenges to global actionDiana Sarfati, Rachel Dyer, Paula Vivili, et al.
Pageof 336